We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Lipoxen | LSE:LPX | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.875 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 7.875 | GBX |
Lipoxen (LPX) Share Charts1 Year Lipoxen Chart |
|
1 Month Lipoxen Chart |
Intraday Lipoxen Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 01/4/2019 | 03:23 | Lipoxen : A small company with blockbuster potential | 1,001 |
| 31/3/2010 | 15:42 | Lipoxen | 424 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/10/2011 20:08 by aimshares Holder of Lpx and Vrp . |
Posted at 06/9/2011 08:58 by the_doctor gregoryan, then I'm interested to hear why you think it's relevantI've given one possibility, saying that Sybiotech wanted the technology to use and Lipoxen wanted drug candidates to develop Whether that's the case or not, I dont know! 123asd I suggest you just maybe dont understand the logic then! The stock price offered and the number of shares are a bit of a red herring as far as other investors are concerned. I dont think you understand quite how paper transactions like this work in reality The price is irrelevant - it's only the number of shares that really matter - and what Symbiotec holders can get for them when they sell 'which is what I suspect he enjoys doing' then he's a bit of a saddo |
Posted at 06/9/2011 08:19 by the_doctor IMO, Lipoxen went for this low-price placing because they couldnt get cash in through any other wayThey have IMO acquired Synbio because they want to move away from their old, struggling technology platform There is a MASSIVE overhang at 11p There are ex-Symbiotec investors who will be desperate to sell their new Lipoxen stock!! Look at the facts, they sold out Symbiotec didnt they The £8.8m stock price is irrelevant - what really matters is the price that Symbiotec hope to get out of it. If they'd be happy with £5m say, then they'll just dump the lot asap. Why should they hold on? YOU HAVE BEEN WARNED OH and LOOK |
Posted at 04/9/2011 17:19 by the_doctor 123asdSymbioTec could sell at any price - the old owners may just want to get their cash. The 11p isnt as relevant as you make out. SymbioTec did not BUY shares at 11p, they were given them in exchange for their business. 'why would SynBio buy £14mil of shares at 11p if there going down to 4p or 5p' 1. because it's in effect a licensing deal. think about this - company x wants to use Lipoxen's tech if they took a license paying £2m upfront, you'd think nothing of that well, because in a normal upfront, you get no shares, that's the same basically as instead paying into a placing for shares at an impossibly high price here, they in effect paid upfront, but got shares for it that's better for Synbio than a straight upfront payment So, dont read too much into the 11p 2. I'll give you an example. AZ did a deal for SLN's tech, getting an equity stake The price paid was something like 120p A few years later, the shares are now at 2p Your argument of 'why would they buy shares if they're going to go down' is considerably less relevant than you make out I posted the views because your friend buywell decided to post further deramps on other stocks If you dont like it, discourage him from doing so |
Posted at 20/8/2011 12:05 by 123asd sicilian_ken - have you read the 4th August RNS? If you have, you will know that, despite the Russians taking a 30% (after dilution) stake in LPX, there will be legal safeguards in the agreement for its successor Xenetic's independence. The whole purpose of this move by Lipo is to accelerate orphan drugs to market, and this deal looks to promote a symbiotic relationship, since the Russian's need LPX's technology and patents. Of course there are risks, but in my opinion it is unhelpful, if not downright disingenuous, to make inflammatory statements such as you make above. |
Posted at 06/8/2011 10:06 by buywell2 Lipoxen in transforming Russian deal 05/08/2011 Robert Tyerman Russian pharmaceutical player Dmitry Genkin's SynBio company is paying £12.2 million for 30 per cent of drug discoverer Lipoxen (LPX). In a series of transformational deals, SynBio is paying a premium 11p a share for a placing by AIM-quoted Lipoxen, which is also issuing premium-priced shares and warrants to major shareholder Serum Institute of India (SIL) and proposing to change its name from Lipoxen to Xenetic Biosciences. After raising £14.4 million from SynBio, SIL and a hoped-for £1.95 million from an open offer to shareholders, London-based Lipoxen says it intends to buy German-registered leukaemia specialist SymbioTech, where a Genkin-controlled company is a significant shareholder, for £8.8 million in shares. Lipioxen/Xenetic will also licence six of its product candidates to SynBio in Russia and regain from SIL development rights to 14 drug candidates. Scott Maguire, chief executive officer of Lipoxen, argues these deals 'will afford the company independence as a speciality drug developer with high-value orphan drug product candidates which have shorter-term market launch potential.' Investors have reacted coolly and Lipoxen shares, which hit 75p nine years ago, are 0.13p off today at 8.75p, valuing the company at £15 million. They have speculative potential. Note Dr Dmitry D Genkin Non-executive Director Dr Dmitry Genkin joined Lipoxen as a non-executive Director in 2000. He has the Russian equivalent of an MD in Internal Therapy and has attended training courses in drug delivery at The School of Pharmacy, University of London (1992) and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm (1992-1993). Dmitry was formerly Chief Executive Officer of ASGL Research Laboratories ZAO, a company which he founded in 1994 to run drug development programmes focusing on viral and cancer diseases. He also served as executive Chairman of Pharmavit OAO and Scientific Director of Pharmavit Holding ZAO. Dmitry is currently a partner and director of FDS Pharma. |
Posted at 05/8/2011 02:26 by 123asd buywell - you have a habit of over-egging the pudding: yes, the RNS is good news and yes the fact that the placing is at a premium to the share price can be seen as a vote of confidence from our new major share holder, but to say that fundraising "is usually at a discount of circa 30%" is simply not true. As for the issue of a possible Russian listing - I floated that thought for discussion for a couple of reasons: it's well known that Mr Maguire has long regarded LPX as undervalued - nothing unusual in that from a CEO - but I did hear a rumour a year or so ago that LPX was looking at a NASDAQ listing as a possibility, but that that idea was shelved as being expensive and ultimately unproductive. Fast forward to now, and in addition to our very important collaborative partner Farmsyntez we also have another, major new Russian investor who is backed by sovereign funds. What could be more logical than that the new company seeks a listing on MICEX in order to attract local participation, in particular Russian IIs, at the same time perhaps improving liquidity and stimulating interest in a sector that the Russian government is reportedly keen to promote. If it happened it would be of huge benefit to us PIs, in my opinion. |
Posted at 04/8/2011 19:09 by the_doctor buywell, you really are a TRUE tw@t!I posted here early today saying that I thought the refinancing was a good result rather than just take the compliment from an honourable man, you instead decided to go posting silly deramping, gloating charts across several threads. You really are a vile character I was perfectly happy to be positive about Lipoxen's deal, but you know what? Maybe the Lipoxen share price is now going to get hammered as shareholders in the acquired company dump to get what they can? There are presumably no deals pending, since if there were, Lipoxen would have hung on and got better prices Just as you've been gloatingly saying 'looks like charts are right' Well, I guess they are buywell millions of shares dumped will see the share price hit 6p IF LIPOXEN's TECH IS ANY GOOD, WHY BUY ANOTHER DIFFERENT COMPANY MASSIVE OVERHANG AT 11p - 110m shares placed! SymbioTec HOLDERS WILL LIKELY WANT AN EXIT - THAT'S 80m shares to come onto the market OH and LOOK Two can play at your game buywell YET AGAIN, you went out of your way to deramp, even after I posted only a positive comment on here |
Posted at 24/7/2011 12:12 by buywell2 Moving averages are converging .... which if we have +ve RNS news soon , could mean another lift in share price like it did autumn 2010 |
Posted at 06/5/2011 02:56 by 123asd Buywell - All very positive, though in common with other recent RNSs, very much long term. Since I bought into LPX eight months ago we have had nothing but positive news from the Company, and this has been reflected in the improved share price, at least until recently. However, I sense that, quite apart from the shaky wider market, investors looking at LPX now are keen to know how the Company will fund itself going forward; from reading the published information, it is clear that, with their cash burn, they will shortly require more funding. I know from his own statements that Mr Maguire has been working on precisely this issue in the past few months, in particular commercial deals that will provide an income stream. This of course takes time, what with the legalities etc, hence the relative paucity of news so far this year. However, I believe we are due, or even overdue, a Prelims statement, and also the AGM should be announced soon, and I am hopeful that we will at the same time get some positive news on the funding front. Maybe that will put an end to the drift lower of the share price in the past couple of months. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
